TIKOMED’S ILB® attenuates clinical symptoms and serum biomarkers of oxidative/nitrosative stress and mitochondrial dysfunction in patients with ALS in data published by the Journal of Personalized Medicine

Viken – 16th August 2021 – New study results for Tikomed’s platform lead drug candidate ILB® in the treatment of patients with amyotrophic lateral sclerosis (ALS), have now been published in the Journal of Personalized Medicine. The data revealed a significant normalization of the serum levels of several key metabolites in addition to a significant improvement of patients’ clinical conditions for the duration of the ILB® treatment period. The treatment response appears to be mediated by improvement of tissue bioenergetics, decrease of oxidative/nitrosative stress and attenuation of (neuro)inflammatory processes.

The deranged neuronal function associated with the oxidative/nitrosative stress and mitochondrial dysfunction characterized by the pathophysiological progress of neurodegenerative conditions such as ALS1 is reflected by changes in related metabolites in blood. When measured, these metabolites can be used as biomarkers of tissue function and, therefore, of disease progression and/or patient response to treatment2. In this study of a cohort of patients with ALS who had participated in the clinical trial entitled ‘A single-centre, open single-arm study on the safety, tolerability and efficacy of subcutaneously administered ILB® in patients with amyotrophic lateral sclerosis’3, repeated ILB® administration over four weeks led to a significant attenuation of the levels of key serum metabolites related to neural damage, oxidative/nitrosative stress and mitochondrial derangement. For full study details please access the publication here.

“We are very pleased that these results strongly suggest that ILB® treatment produces metabolic benefits corresponding with the encouraging clinical improvements seen for the ALS patients participating in this study”, said Anders Kristensson, CEO of Tikomed. “The adaptive, multi modal mechanism of action of ILB® and the growing scientific evidence supporting it’s ability to rebalance the body’s own inflammatory response and enhance endogenous repair mechanisms gives us the limitless potential to pursue all disease areas driven by uncontrolled or dysfunctional inflammation, on our quest to provide safe and affordable medicines to as many patients as possible across the globe”.

Journal of Personalized Medicine is an international, peer-reviewed, open access journal on personalized medicine published monthly online by MDPI. For full study details please access the publication here.

References

1. Le Gall, L.; Anakor, E.; Connolly, O.; Vijayakumar, U.G.; Duddy, W.J.; Duguez, S. Molecular and cellular mechanisms affected in ALS. J. Pers. Med. 2020, 10, 101.

2. Aydemir, D.; Ulusu, N.N. Importance of the serum biochemical parameters as potential biomarkers for rapid diagnosis and evaluating preclinical stage of ALS. Med. Hypotheses 2020, 141, 109736.

3. A Single-Centre, Open Single-Arm Study Where the Safety, Tolerability and Efficacy of Subcutaneously Administered ILB Will Be Evaluated in Patients with Amyotrophic Lateral Sclerosis. Available online.

Share on facebook
Share on twitter
Share on linkedin
Share on email